Pharmacological activity of DC-015, a novel potent and selective α1-adrenoceptor antagonist

M. H. Yen, J. R. Sheu, I. H. Peng, Y. M. Lee, J. W. Chern

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The pharmacological activity of 3-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-2,3-dihydroimidazo(1,2 -c)quinazolin-5(6H)-one (DC-015), a newly synthesized quinazoline derivative, was determined in rat isolated thoracic aorta and presser responses were determined in spontaneously hypertensive rats (SHR). Experimental results indicated that DC-015 is an α1-adrenoceptor-blocking agent in rat thoracic aorta as revealed by its competitive antagonism of phenylephrine-induced vasocontraction (pA2 = 10.54 ± 0.55). These effects still persisted in denuded aorta. It was as potent as prazosin pA2 = 10.04 ± 0.63). At higher concentrations (10 μM), DC-015 also expressed 5-hydroxytryptamine (5-HT) receptor competitive antagonism, but this 5-HT blocking effect was not found in the prazosin-administration group. [3H]Inositol monophosphate formation stimulated by phenylephrine (30 μM) in rat thoracic aorta was diminished by DC-015 (3 and 10 nM) and prazosin (10 nM); whereas the cAMP content of rat thoracic aorta was not altered by DC-015 and prazosin. Furthermore, intravenous administration of DC-015 and prazosin (both at 0.01, 0.05 and 0.1 mg kg-1) induced a dose-dependent reduction of mean arterial pressure which reached a maximal effect at 5 min after injection and persisted over 2 h in SHR. A higher dose of DC-015 (0.1 mg kg-1, i.v.) did not cause any significant changes in heart rate, whereas, the same dose of prazosin (0.1 mg kg-1, i.v.) produced a decrease which seems to parallel the time course of the hypotensive response. We can conclude that the DC-015 is a potent, highly selective α1-adrenoceptor antagonist in vascular smooth muscle.

Original languageEnglish
Pages (from-to)90-95
Number of pages6
JournalJournal of Pharmacy and Pharmacology
Volume48
Issue number1
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Adrenergic Receptors
Prazosin
Pharmacology
Thoracic Aorta
Phenylephrine
Inbred SHR Rats
Quinazolines
DC 015
Serotonin Receptors
Inositol
Vascular Smooth Muscle
Intravenous Administration
Aorta
Serotonin
Arterial Pressure
Heart Rate
Injections

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Pharmacological activity of DC-015, a novel potent and selective α1-adrenoceptor antagonist. / Yen, M. H.; Sheu, J. R.; Peng, I. H.; Lee, Y. M.; Chern, J. W.

In: Journal of Pharmacy and Pharmacology, Vol. 48, No. 1, 1996, p. 90-95.

Research output: Contribution to journalArticle

Yen, M. H. ; Sheu, J. R. ; Peng, I. H. ; Lee, Y. M. ; Chern, J. W. / Pharmacological activity of DC-015, a novel potent and selective α1-adrenoceptor antagonist. In: Journal of Pharmacy and Pharmacology. 1996 ; Vol. 48, No. 1. pp. 90-95.
@article{731f48461c644662b053bce42b791696,
title = "Pharmacological activity of DC-015, a novel potent and selective α1-adrenoceptor antagonist",
abstract = "The pharmacological activity of 3-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-2,3-dihydroimidazo(1,2 -c)quinazolin-5(6H)-one (DC-015), a newly synthesized quinazoline derivative, was determined in rat isolated thoracic aorta and presser responses were determined in spontaneously hypertensive rats (SHR). Experimental results indicated that DC-015 is an α1-adrenoceptor-blocking agent in rat thoracic aorta as revealed by its competitive antagonism of phenylephrine-induced vasocontraction (pA2 = 10.54 ± 0.55). These effects still persisted in denuded aorta. It was as potent as prazosin pA2 = 10.04 ± 0.63). At higher concentrations (10 μM), DC-015 also expressed 5-hydroxytryptamine (5-HT) receptor competitive antagonism, but this 5-HT blocking effect was not found in the prazosin-administration group. [3H]Inositol monophosphate formation stimulated by phenylephrine (30 μM) in rat thoracic aorta was diminished by DC-015 (3 and 10 nM) and prazosin (10 nM); whereas the cAMP content of rat thoracic aorta was not altered by DC-015 and prazosin. Furthermore, intravenous administration of DC-015 and prazosin (both at 0.01, 0.05 and 0.1 mg kg-1) induced a dose-dependent reduction of mean arterial pressure which reached a maximal effect at 5 min after injection and persisted over 2 h in SHR. A higher dose of DC-015 (0.1 mg kg-1, i.v.) did not cause any significant changes in heart rate, whereas, the same dose of prazosin (0.1 mg kg-1, i.v.) produced a decrease which seems to parallel the time course of the hypotensive response. We can conclude that the DC-015 is a potent, highly selective α1-adrenoceptor antagonist in vascular smooth muscle.",
author = "Yen, {M. H.} and Sheu, {J. R.} and Peng, {I. H.} and Lee, {Y. M.} and Chern, {J. W.}",
year = "1996",
language = "English",
volume = "48",
pages = "90--95",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "1",

}

TY - JOUR

T1 - Pharmacological activity of DC-015, a novel potent and selective α1-adrenoceptor antagonist

AU - Yen, M. H.

AU - Sheu, J. R.

AU - Peng, I. H.

AU - Lee, Y. M.

AU - Chern, J. W.

PY - 1996

Y1 - 1996

N2 - The pharmacological activity of 3-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-2,3-dihydroimidazo(1,2 -c)quinazolin-5(6H)-one (DC-015), a newly synthesized quinazoline derivative, was determined in rat isolated thoracic aorta and presser responses were determined in spontaneously hypertensive rats (SHR). Experimental results indicated that DC-015 is an α1-adrenoceptor-blocking agent in rat thoracic aorta as revealed by its competitive antagonism of phenylephrine-induced vasocontraction (pA2 = 10.54 ± 0.55). These effects still persisted in denuded aorta. It was as potent as prazosin pA2 = 10.04 ± 0.63). At higher concentrations (10 μM), DC-015 also expressed 5-hydroxytryptamine (5-HT) receptor competitive antagonism, but this 5-HT blocking effect was not found in the prazosin-administration group. [3H]Inositol monophosphate formation stimulated by phenylephrine (30 μM) in rat thoracic aorta was diminished by DC-015 (3 and 10 nM) and prazosin (10 nM); whereas the cAMP content of rat thoracic aorta was not altered by DC-015 and prazosin. Furthermore, intravenous administration of DC-015 and prazosin (both at 0.01, 0.05 and 0.1 mg kg-1) induced a dose-dependent reduction of mean arterial pressure which reached a maximal effect at 5 min after injection and persisted over 2 h in SHR. A higher dose of DC-015 (0.1 mg kg-1, i.v.) did not cause any significant changes in heart rate, whereas, the same dose of prazosin (0.1 mg kg-1, i.v.) produced a decrease which seems to parallel the time course of the hypotensive response. We can conclude that the DC-015 is a potent, highly selective α1-adrenoceptor antagonist in vascular smooth muscle.

AB - The pharmacological activity of 3-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-2,3-dihydroimidazo(1,2 -c)quinazolin-5(6H)-one (DC-015), a newly synthesized quinazoline derivative, was determined in rat isolated thoracic aorta and presser responses were determined in spontaneously hypertensive rats (SHR). Experimental results indicated that DC-015 is an α1-adrenoceptor-blocking agent in rat thoracic aorta as revealed by its competitive antagonism of phenylephrine-induced vasocontraction (pA2 = 10.54 ± 0.55). These effects still persisted in denuded aorta. It was as potent as prazosin pA2 = 10.04 ± 0.63). At higher concentrations (10 μM), DC-015 also expressed 5-hydroxytryptamine (5-HT) receptor competitive antagonism, but this 5-HT blocking effect was not found in the prazosin-administration group. [3H]Inositol monophosphate formation stimulated by phenylephrine (30 μM) in rat thoracic aorta was diminished by DC-015 (3 and 10 nM) and prazosin (10 nM); whereas the cAMP content of rat thoracic aorta was not altered by DC-015 and prazosin. Furthermore, intravenous administration of DC-015 and prazosin (both at 0.01, 0.05 and 0.1 mg kg-1) induced a dose-dependent reduction of mean arterial pressure which reached a maximal effect at 5 min after injection and persisted over 2 h in SHR. A higher dose of DC-015 (0.1 mg kg-1, i.v.) did not cause any significant changes in heart rate, whereas, the same dose of prazosin (0.1 mg kg-1, i.v.) produced a decrease which seems to parallel the time course of the hypotensive response. We can conclude that the DC-015 is a potent, highly selective α1-adrenoceptor antagonist in vascular smooth muscle.

UR - http://www.scopus.com/inward/record.url?scp=0029997686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029997686&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 90

EP - 95

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 1

ER -